沙利度胺联用TP方案化疗对晚期NSCLC患者血清肿瘤标志物的影响

Effects of Thalidomide Combined with TP Regimen Chemotherapy on Serum Tumor Markers in Patients with Advanced NSCLC

目的探讨晚期非小细胞肺癌(NSCLC)患者采用沙利度胺联用TP方案化疗对其血清肿瘤标志物的影响。方法选取我院2016年4月~2018年1月收治的96例晚期NSCLC患者为研究对象,按单盲法分为对照组和观察组,各48例。对照组采用TP方案化疗,在此基础上,观察组联用沙利度胺治疗,连续治疗4个周期。比较两组临床疗效、血清肿瘤标志物与血管内皮生长因子(VEGF)水平、毒副反应。结果化疗后,观察组总有效率较对照组高,细胞角蛋白19片段(CYFRA21 - 1),血清癌抗原125(CA125)、癌胚抗原(CEA)、VEGF水平均较对照组低,恶心呕吐、嗜睡、便秘等发生率均较对照组低,差异具有统计学意义(P<0.05);两组白细胞减少率差异无统计学意义(P>0.05)。结论晚期NSCLC患者采用沙利度胺联用TP方案化疗可提高临床疗效,降低血清肿瘤标志物及VEGF水平,毒副反应少,安全性较高。

Objective To investigate effects of thalidomide combined with TP regimen chemotherapy on serum tumor markers in patients with advanced non - small cell lung cancer( NSCLC). Methods 96 patients with advanced NSCLC in the hospital from Apr. 2016 to Jan. 2018 were selected. They were divided into control group and observation group by blind trial with 48 cases in each group. TP regimen chemotherapy was used in control group, while patients in observation group were treated with thalidomide based on control group with 4 courses of treatment in each group. The clinical efficacy,levels of serum tumor markers and vascular endothelial growth factor( VEGF) as well as toxic - side reactions were compared between the two groups. Results The total effective rate in observation group was higher than that in control group after chemotherapy. The levels of cytokeratin 19 fragment ( CYFRA21 - 1), serum cancer antigen 125( CAI25) and VEGF in observation group were lower than those in control group. The incidences of nausea and vomiting, somnolence, constipation in observation group were lower than that in control group(P < 0. 05). There was no significant difference in the incidence of leukopenia between the two groups (P >0. 05). Conclusion Thalidomide combined with TP regimen chemotherapy on patients with advanced NSCLC can increase clinical efficacy ,decrease levels of serum tumor markers and VEGF,which have less toxic - side reactions and higher safety.